Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events
NCT04375228Phase 2Active, not recruiting
- Sponsor
- Columbia University
- Start
- Sep 2020
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, tocilizumab in immune-related adverse events (irAEs), sponsored by Columbia University. Started Sep 2020; status: active, not recruiting.
02
Drugs
rituximabtocilizumab
03
Conditions
immune-related adverse events (irAEs)
Beyond the preview
Go deeper on NCT04375228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375228.